Global experience with ixabepilone in breast cancer

Area of Science:

• Oncology
• Pharmacology
• Clinical Therapeutics

Background:

• Ixabepilone is approved globally for advanced breast cancer, often used in later lines of therapy.
• Limited data exist on ixabepilone's use in diverse ethnic populations.
• Understanding ethnic variations is crucial for personalized cancer treatment.

Purpose of the Study:

• To evaluate the disposition, efficacy, and tolerability of ixabepilone in different ethnic subgroups.
• To analyze global patterns of ixabepilone utilization.
• To identify factors influencing ixabepilone's real-world application.

Main Methods:

• Review of data from pivotal trials and post-marketing surveillance.
• Analysis of pharmacokinetic and pharmacodynamic data in ethnic subgroups (Hispanic, Japanese, Chinese).
• Assessment of treatment outcomes and adverse events.

Main Results:

• No clinically significant variations in ixabepilone disposition, efficacy, or tolerability were observed across studied ethnic subgroups.
• Ixabepilone demonstrated a consistent safety and efficacy profile compared to pivotal trial data.
• Global use is influenced by regulatory, guideline, and economic factors.

Conclusions:

• Ixabepilone's established profile is applicable across diverse ethnic backgrounds.
• Optimizing ixabepilone use requires consideration of local regulatory and clinical practice variations.
• Further research into global usage patterns can enhance therapeutic strategies.